XBiotech Inc.
$2.51
▲
0.43%
2026-04-21 10:20:02
www.xbiotech.com
NMS: XBIT
Explore XBiotech Inc. stock price, valuation, financial statements, dividend history, analyst estimates, and long-term business fundamentals on StockSifting.
Market Cap
$78.32 M
Current Price
$2.51
52W High / Low
$3.61 / $2.09
Stock P/E
—
Book Value
$4.6
Dividend Yield
—
ROCE
-39.17%
ROE
-28.23%
Face Value
—
EPS
$-1.49
Exp Qtr EPS
—
Sector
Healthcare
Industry
Biotechnology
Employees
85
Beta
0.83
Debt / Equity
—
Current Ratio
16.01
Quick Ratio
16.01
Forward P/E
17.92
Price / Sales
—
Enterprise Value
$-54.51 M
EV / EBITDA
1.01
EV / Revenue
—
Rating
None
Target Price
—
EPS Forecast (FY)
—
Pros
- Short-term liquidity looks comfortable.
Cons
- Return on equity is on the weaker side.
- Capital efficiency is modest.
- Operating margin is thin.
- Net margin is relatively low.
Sift Stocks
| S.No. | Name | Price | P.E. | Market Cap | Div Yld % | ROCE | ROE | 52Week High/ Low | Book Value |
|---|---|---|---|---|---|---|---|---|---|
| 1. | Alto Neuroscience, Inc. | $27.33 | — | $885.53 M | — | -38.28% | -41.8% | $28.11 / $2.09 | $4.74 |
| 2. | Ultragenyx Pharmaceutical Inc. | $25.06 | — | $2.39 B | — | -46.6% | -6.08% | $42.37 / $18.29 | $-0.83 |
| 3. | Pulmatrix, Inc. | $1.34 | — | $4.91 M | — | -135.67% | -80.93% | $9.37 / $1.16 | $1.04 |
| 4. | Atrium Therapeutics, Inc. | $14.3 | — | $239.4 M | — | -32.47% | -104.92% | $73.06 / $11.95 | $-4.04 |
| 5. | Curis, Inc. | $0.62 | — | $24.33 M | — | -558.61% | 2829.1% | $3.13 / $0.49 | $0.42 |
| 6. | Milestone Pharmaceuticals Inc. | $2.04 | — | $247.1 M | — | -62.4% | -2.3% | $3.06 / $0.77 | $0.34 |
| 7. | Vyome Holdings, Inc. | $2.35 | — | $16.49 M | — | -73.02% | 1053.07% | $56.36 / $1.75 | $0.41 |
Quarterly Results
Figures shown in M / B
| Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | |
|---|---|---|---|---|---|---|
| Sales | 0 M | 0 M | 0 M | 0 M | 0 M | — |
| Operating Profit | -29.75 M | -6.05 M | -6.34 M | -13.55 M | -8.75 M | — |
| Net Profit | -26.89 M | -6.01 M | -1.76 M | -10.88 M | -10.51 M | — |
| EPS in Rs | -0.88 | -0.2 | -0.06 | -0.36 | -0.34 | -0.16 |
Profit & Loss
Figures shown in M / B
| 2025 | 2024 | 2023 | 2022 | |
|---|---|---|---|---|
| Sales | 0 M | 0 M | 0 M | 4.01 M |
| Operating Profit | -55.69 M | -42.47 M | -37.51 M | -34.49 M |
| Net Profit | -45.54 M | -38.53 M | -24.56 M | -32.9 M |
| EPS in Rs | -1.49 | -1.26 | -0.81 | -1.08 |
Balance Sheet
Figures shown in M / B
| 2025 | 2024 | 2023 | 2022 | |
|---|---|---|---|---|
| Total Assets | 150.08 M | 199.09 M | 226.62 M | 246.1 M |
| Total Liabilities | 9.73 M | 16.82 M | 7.77 M | 5.7 M |
| Equity | 140.35 M | 182.27 M | 218.85 M | 240.4 M |
| Current Assets | 126.95 M | 174.57 M | 201.72 M | 219.84 M |
| Current Liabilities | 7.93 M | 15.11 M | 6.1 M | 4.07 M |
Cash Flow
Last available yearly cash flow history
| 2025 | 2024 | 2023 | 2022 | |
|---|---|---|---|---|
| Operating CF | -39.92 M | -30.96 M | -18.73 M | -14.82 M |
| Investing CF | -0.29 M | -1.3 M | 61.5 M | -63.89 M |
| Financing CF | -10.25 M | 10.45 M | -0.01 M | 0 M |
| Free CF | -40.21 M | -32.27 M | -19.09 M | -15.41 M |
| Capex | -0.29 M | -1.3 M | -0.36 M | -0.58 M |
5Y Margin & Growth History
Last 5 year derived history from yfinance annual statements
| 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|
| Revenue Growth % | — | -100% | — | — |
| Earnings Growth % | -56.9% | 25.36% | — | — |
| Profit Margin % | — | — | -820.45% | — |
| Operating Margin % | — | — | -860.1% | — |
| Gross Margin % | — | — | 83.77% | — |
| EBITDA Margin % | — | — | -794.91% | — |
Dividend & Split History
Latest dividend and stock split events stored from yfinance
Dividend History
| Ex Date | Dividend |
|---|---|
| 2021-07-15 | $2.5 |
Stock Splits
No stock split history available.